Document Detail


Febuxostat (Teijin/Ipsen/TAP).
MedLine Citation:
PMID:  16312139     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Febuxostat (TEI-6720; TMX-67), an oral non-purine, selective inhibitor of xanthine oxidase (NP-SIXO), is being developed by Teijin, with licensees Ipsen and TAP Holdings, for the potential treatment of gout. In February 2005, it was reported that launch in Japan was expected to be delayed for several years due to the need for additional clinical trials; in May 2005, an EU filing was expected by the end of 2005.
Authors:
Brian Tomlinson
Related Documents :
22773769 - Effects of transdermal estrogen on collagen turnover at rest and in response to exercis...
22779909 - Novel mouth-exercising device for oral submucous fibrosis.
1950689 - Retrosigmoidal approach to the posterior cranial fossa. an anatomical study.
1554209 - Nasal cannula and transtracheal oxygen delivery. a comparison of patient response after...
18670989 - Aspergillosis and candidiasis in psittacine and passeriforme birds with particular refe...
10230529 - Aerodynamic, acoustic, and perceptual measures of nasality following traumatic brain in...
8761839 - Effects of 2,000 kcal per week of walking and stair climbing on physical fitness and ri...
24276299 - The effect of exercise intensity on post resistance exercise hypotension in trained men.
23236449 - Transient increase in homocysteine but not hyperhomocysteinemia during acute exercise a...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current opinion in investigational drugs (London, England : 2000)     Volume:  6     ISSN:  1472-4472     ISO Abbreviation:  Curr Opin Investig Drugs     Publication Date:  2005 Nov 
Date Detail:
Created Date:  2005-11-29     Completed Date:  2006-06-08     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  100965718     Medline TA:  Curr Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  1168-78     Citation Subset:  IM    
Affiliation:
Division of Clinical Pharmacology, Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, SAR China. btomlinson@cuhk.edu.hk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Drug Evaluation, Preclinical
Enzyme Inhibitors / pharmacokinetics,  pharmacology,  therapeutic use*
Gout / drug therapy*
Humans
Patents as Topic
Randomized Controlled Trials as Topic
Structure-Activity Relationship
Thiazoles / pharmacokinetics,  pharmacology,  therapeutic use*
Xanthine Oxidase / antagonists & inhibitors*
Chemical
Reg. No./Substance:
0/Enzyme Inhibitors; 0/Thiazoles; 144060-53-7/febuxostat; EC 1.17.3.2/Xanthine Oxidase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Potential immunosuppressive therapeutics to target small vessel vasculitis of the kidney.
Next Document:  Velafermin (CuraGen).